MTOR and prostate cancer: Hyper-activation of this pathway, often driven by loss of the tumor suppressor phosphatase and tensin homolog (PTEN) or AKT and mTOR dysregulation, facilitates the transition to castration-resistant prostate cancer by compensating for suppression of androgen receptor signaling.